All News

Information from magnetic resonance imaging and systematic biopsy may be used to identify candidates for partial gland ablation among men with recurrent localized prostate cancer after radiation therapy, researchers from Memorial Sloan Kettering Cancer Center reported at the AUA annual meeting in Boston.

The risk of erectile dysfunction is not increased with the use of a 5-alpha-reductase inhibitor compared with an alpha-blocker for the treatment of BPH.

Early follow-up of men with localized prostate cancer treated with novel technology that integrates fusion biopsy findings to guide high-intensity focused ultrasound (HIFU [Focal One]) shows the technique has promise for minimizing post-treatment morbidity while providing good cancer control, Italian researchers reported at the AUA annual meeting in Boston.

Urologists are no longer the primary initiators of tamsulosin (Flomax) therapy in the United States, suggests an analysis of pharmaceutical claims from more than 50 private health plans.

A recent review of two phase III randomized controlled trials demonstrated that addition of androgen deprivation therapy to salvage pelvic radiation therapy for prostate cancer recurrence after radical prostatectomy reduces the risk of metastases and improves overall survival.

This article provides an overview of the new 2018 ICD-10-CM codes, revisions, and deletions that are relevant to urology practice.

While CMS has demonstrated an ability to listen to providers’ concerns about QPP implementation, many issues still need to be addressed and urologists must continue to be vocal.

After attending an industry dinner, urologist Henry Rosevear, MD, came away with an appreciation for the role of health care economics in bringing a product to market.

In this Urology Times educational supplement, we review the importance of understanding the CRPC–mCRPC transition in order to optimize standard screening procedures and identify patients with early metastatic disease who may benefit from therapeutic intervention.

There are several options for saving for retirement, but first develop a good understanding of how these retirement accounts work to get the most out of your savings.

The development of a model for identifying prostate cancer patients who may be appropriate candidates for hemi-ablative focal therapy remains a work in progress for researchers at Memorial Sloan Kettering Cancer Center.

Researchers from Wake Forest Baptist Comprehensive Cancer Center have made novel discoveries about the genomic signatures of cancers-including bladder cancer-in smokers and African-American patients.

New research characterizing the molecular mechanisms regulating immune cell infiltration into the luminal subtype of muscle-invasive bladder cancer may explain resistance to treatment with immune checkpoint blockade and suggest a target for improving therapeutic response.

The following letter was sent to Urology Times in response to a previously published letter to the editor, "Dear USPSTF: Don't discount value of PSA in men 70+."

Other pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.

Authors of a recent study say that long-term therapy with a 5-alpha-reductase inhibitor was associated with increased glucose, increased glycated hemoglobin, and altered lipid profiles.

In this interview, SUNA President Gwendolyn Hooper, PhD, APRN, discusses practical tips for prevention and management of incontinence in men treated for localized prostate cancer.

In this interview, Leonard G. Gomella, MD, provides an update on prostate cancer genetics, discusses the recent Prostate Cancer International Consensus Conference, and outlines why urologists should conduct more extensive family histories of their prostate cancer patients.

Two electronic Clinical Quality Measures will help urologists report on prostate and bladder cancer care.

In a recent study, increasing hospital volume was significantly associated with improved perioperative outcomes.

Patients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma following platinum-based chemotherapy maintain better health-related quality of life than their counterparts receiving chemotherapy, according to results from the phase III KEYNOTE-045 trial presented at the American Society of Clinical Oncology annual meeting in Chicago.